Unemployment and disability in patients with moderately to severely active Crohn's disease.
about
Management and Complications of Short Bowel Syndrome: an Updated Review.Empowering employees with chronic diseases; development of an intervention aimed at job retention and design of a randomised controlled trial.The impact of the patient-centered medical home on the biologics industry, employers, and third-party payers.Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of LifeDisability in Patients with Inflammatory Bowel Disease: Correlations with Quality of Life and Patient's Characteristics.Opioid use is associated with decreased quality of life in patients with Crohn's disease.Tailoring the treatment to the individual in Crohn's disease.Behavioral interventions may prolong remission in patients with inflammatory bowel disease.The impact of biologics on health-related quality of life in patients with inflammatory bowel disease.Optimizing management of Crohn's disease within a project management framework: results of a pilot study.Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysisIBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study.Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans? Uneasy questions and speculations.Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies.Facilitating empowerment in employees with chronic disease: qualitative analysis of the process of change.Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness.Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.Sick leave and disability pension in inflammatory bowel disease: a systematic review.Intestinal fibrosis in Crohn's disease: role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets.The impact of moderate-to-severe Crohn's Disease on employees' salary growth.Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review.Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.Development and Validation of the Short Crohn's Disease Work Disability Questionnaire.Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.Low Risk of Unemployment, Sick Leave, and Work Disability Among Patients with Inflammatory Bowel Disease: A 7-year Follow-up Study of a Danish Inception Cohort.Low Serum Levels of MicroRNA-19 Are Associated with a Stricturing Crohn's Disease Phenotype.Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.Disability in IBD: the devil is in the details.Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.Development and validation of the Crohn's disease perceived work disability questionnaire.Quality of life in patients with inflammatory bowel disease: importance of clinical, demographic and psychosocial factors.Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.The burden of inflammatory bowel disease on health care utilization and quality of life.Solution focused therapy: a promising new tool in the management of fatigue in Crohn's disease patients psychological interventions for the management of fatigue in Crohn's disease.
P2860
Q30249483-303843B4-A8ED-4786-AB5E-3F07E3A04A48Q33382516-84F83E1B-9B78-431F-83A1-8A2468AD265CQ33629056-ACCA4ED2-7460-4659-B322-9D687526A9B4Q33638449-6A072865-F65D-4080-B2B0-6533992339BFQ33786688-0E3288DE-1002-4B2E-B847-58B526C4D74DQ33796046-B5EC5B97-99FF-4C92-ADC6-EE84C68B0F6BQ34409001-DB1583A9-6592-4558-B2DB-D45927416B16Q34590491-F0B294F3-4DDE-4C53-9046-DF0DAD598329Q35026298-0E485C36-0009-46A2-B127-22124FB37F3FQ35036687-90164203-61E6-45DB-9C66-F827E237A9B3Q35268107-03FC42B7-1F56-4563-9475-6CED86440DB0Q35452972-9F58AC31-9EFD-4069-B9BE-3664121A5272Q35926068-22859A53-6CAF-4206-B95B-0E75F5059E20Q36860982-53A1C3E1-A319-477B-9ACB-EF85AA0BF14CQ37346051-98EC7DED-815D-4F4E-A099-1B93401A54C4Q37416160-69F2B041-563A-4C46-9E1E-8ECA7399BB79Q37528116-C00AE174-6CD4-4B94-88AF-D08C429CB646Q37684572-91D4A510-0683-4A13-B05D-B32B793646F0Q37947158-FED7428C-B750-4A9C-82A9-EB0782B790C3Q38227060-163AF89B-9666-40EF-9073-8150D3E0099EQ38337742-D11A50EA-9EBB-424B-B847-DC8A61017695Q38419603-AE773D2C-25F0-49F0-A93E-E19F92B517A7Q38430984-5595D6C0-E730-41A7-8DA2-EA30A74E0FD3Q38488635-AFDBA71B-E7DD-472D-BB16-2EF839952AF2Q38845478-12CFF91B-C9AD-458B-8D2D-A52AD6948170Q39557707-57791E97-97FD-42A6-BE4A-F6270DCE1912Q40657731-8042DBE7-38C4-4810-8CD9-32FE13DA0695Q40747902-27B0D170-F24D-407A-BF54-BA430A3BDB8DQ40928156-3CF88D34-FBE8-44E4-B380-A25CD64BBBFBQ43263384-48AAC54D-A179-4E14-8CD1-EC7028623EB9Q44878711-3FC2E71F-710F-4761-8562-7D4DAF808D12Q45181725-C98963A3-586A-4A54-B732-816B03234503Q45376630-69876A0B-B9F3-4933-8B8F-A61BD130B1A1Q45718672-2CB8F793-B8A1-4CBD-A39E-FFD24B202162Q47155609-EC93267A-907D-4270-8FB7-4A55CAC3C82BQ47382818-E97DF262-4727-4115-8732-A12A6E812EFBQ47720829-287333F5-EF82-4B28-8E1D-A88611ADE84BQ48106537-A4B7571D-B326-4A32-9BDD-9FE9887F1AB1Q48444160-3C8E86ED-B68A-484B-9D89-6832272CA5E5Q48536522-C6A5107E-0C7E-4DD7-A6A5-644658D11779
P2860
Unemployment and disability in patients with moderately to severely active Crohn's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Unemployment and disability in ...... verely active Crohn's disease.
@en
type
label
Unemployment and disability in ...... verely active Crohn's disease.
@en
prefLabel
Unemployment and disability in ...... verely active Crohn's disease.
@en
P2093
P1476
Unemployment and disability in ...... verely active Crohn's disease.
@en
P2093
Allan Olson
Mohan Bala
Songkai Yan
Stephen Hanauer
P304
P356
10.1097/01.MCG.0000159220.70290.41
P577
2005-05-01T00:00:00Z